Alnylam Pharmaceuticals and Viz.ai have entered into a strategic partnership that will deploy Viz.ai’s AI‑powered diagnostic platform to identify patients with transthyretin‑mediated cardiac amyloidosis (ATTR‑CM) earlier and standardize the evaluation process. The collaboration will use Viz.ai’s FDA‑cleared echocardiography AI algorithm, Us2.ai, and its broader Viz Cardio Suite, which is already integrated into more than 2,000 hospitals nationwide, to flag potential ATTR‑CM cases and trigger a coordinated care pathway that can move patients toward Alnylam’s RNAi therapies more quickly.
The two companies will launch the AWARE study, a prospective implementation trial that will evaluate the impact of AI‑enabled screening on diagnostic timelines and care coordination. Five pilot health systems will run the study, measuring how quickly patients move from initial imaging to definitive diagnosis and treatment initiation. The study’s results will inform broader deployment of the platform across Viz.ai’s network and Alnylam’s commercial strategy.
Alnylam’s AMVUTTRA (vutrisiran) and ONPATTRO (patisiran) have driven the company’s recent revenue growth and profitability, and the partnership supports Alnylam’s broader goal of expanding patient access to its ATTR‑CM therapies. AMVUTTRA competes with Pfizer’s tafamidis and BridgeBio’s acoramidis, and earlier diagnosis is critical for maximizing the therapeutic window of these treatments. By improving detection rates, the partnership could increase the patient pool that Alnylam can serve and strengthen its competitive position in the cardiomyopathy space.
Viz.ai’s platform, built on advanced imaging and generative AI, will be integrated into clinical workflows to identify ATTR‑CM patients earlier. The company’s Viz Cardio Suite already serves thousands of hospitals, and the partnership will expand its reach into the ATTR‑CM market, providing clinicians with actionable insights that can reduce diagnostic delays and improve outcomes.
"Earlier recognition can fundamentally change a patient's course of disease," said Sameer Bansilal, Vice President, Global TTR Medical Lead at Alnylam Pharmaceuticals. "This partnership is about making early detection actionable. By combining advanced imaging and generative AI with a care coordination platform, we will help clinicians find the right patients earlier and move them swiftly toward appropriate care before the window for meaningful intervention narrows," added Tim Showalter, MD, Chief Medical Officer of Viz.ai.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.